RightAnswer Knowledge Solutions Search Results for 16941-32-5

New Search  |  Search Results (16941-32-5)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Handling/Storage/Shipping/Waste Management
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

MEDITEXT® Documentshelp


All Other Data Sources:

DART Documentshelp
ECOTOX Documentshelp
HSDB® Data Bankhelp
LOLI® Listingshelp
REPROTOX® Documentshelp
RTECS® Registryhelp
Shepard's Cataloghelp
MSDSonline®help

ChemID External Links:


Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for 16941-32-5:


Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

  1. USES: Glucagon is indicated for the treatment of severe hypoglycemia, and to treat beta blocker overdose and less commonly calcium channel blocker overdose. It may also be used as a diagnostic aid and to treat esophageal foreign bodies.
  1. PHARMACOLOGY: Glucagon induces liver glycogen breakdown, releasing glucose from the liver. Hepatic stores of glycogen are needed for glucagon to produce an antihypoglycemic effect. Binding of glucagon to receptors on the heart stimulates conversion of DTP to cyclic AMP, which increases heart rate and strength of contraction.
  1. EPIDEMIOLOGY: Overdose is uncommon.
  1. WITH THERAPEUTIC USE
    1. ADVERSE EFFECTS: Nausea and vomiting may be expected. Severe reactions are not anticipated. Reactive hypoglycemia can develop following the administration of glucagon. Hypokalemia may also occur. Acute allergic reactions (including urticaria, respiratory distress, and hypotension) have been reported rarely following intravenous administration.
  1. WITH POISONING/EXPOSURE
    1. MILD TO MODERATE TOXICITY: Symptoms of nausea, vomiting, gastric hypotonicity and diarrhea would be expected following overdose. Toxicity is anticipated to be an extension of adverse events reported and may include: hyperglycemia or hypoglycemia, hypokalemia, and an increase in blood pressure.
    1. SEVERE TOXICITY: Based on its short half-life, significant protracted overdose effects are not expected to develop.
© 2011-2017 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.